After having a lot of problems posting
over on Yahoo, I think I'll stay here,
apologies to the thread and the folks
over on yahoo who lurk here for having
made so much noise.
the post over there to read is aria #633
messages.yahoo.com@m2.yahoo.com
Anyway, the most recent patent which comes up when
you do a title search for aav turns up...
United States Patent
5,856,152
Wilson , et al.
January 5, 1999
Hybrid adenovirus-AAV vector and methods of use therefor
Abstract
The present invention provides a hybrid vector construct which
comprises a portion of an adenovirus, 5' and 3' ITR sequences
from an AAV, and a selected transgene. Other hybrid vectors form
a polycation conjugate and incorporate an AAV rep gene in a single
particle. These hybrid virus vectors are characterized by high titer
transgene delivery to a host cell and the ability to stably integrate
the transgene into the host cell chromosome. Also disclosed is the
use of the hybrid vectors to produce large quantities of recombinant AAV.
Inventors:
Wilson; James M. (Gladwyne, PA); Kelley; William M. (Ann Arbor, MI); Fisher; Krishna J. (Philadelphia, PA)
Assignee:
The Trustees of the University of Pennsylvania (Philadelphia, PA)
Appl. No.: 331384
Filed: October 28, 1994
Here is the SUMMARY OF THE INVENTION
In one aspect, the present invention provides a unique hybrid
adenovirus/AAV viral particle, which comprises an adenovirus
capsid containing selected portions of an adenovirus sequence,
5' and 3' AAV ITR sequences which flank a selected transgene
under the control of a selected promoter and other conventional
vector regulatory components. This hybrid viral particle is
characterized by high titer transgene delivery to a host cell
and the ability to stably integrate the transgene into the
host cell chromosome. In one embodiment, the transgene is a
reporter gene. Another embodiment of the hybrid viral particle
contains a therapeutic transgene. Still another embodiment of
the hybrid vector particle has associated therewith a polycation
sequence. Another embodiment of the hybrid viral particle also
includes an AAV rep gene.
In another aspect, the present invention provides a hybrid vector
construct for use in producing the viral particle described above.
This hybrid vector comprises selected portions of an adenovirus
sequence, 5' and 3' AAV ITR sequences which flank a selected
transgene under the control of a selected promoter and other
conventional vector regulatory components. Another embodiment of
the hybrid viral particle also includes an AAV rep gene.
In another aspect, the invention provides a method for delivering
a selected gene to a host cell for expression in that cell by
employing the hybrid viral particle of this invention. Such a method
may be employed to deliver a therapeutic gene to a targeted host cell
to treat or correct a genetically associated disorder or disease.
In yet another aspect, the present invention provides a method for producing the hybrid viral particle by transfecting a suitable
packaging cell line with the hybrid construct of this invention.
In another embodiment the method involves co-transfecting a cell
line (either a packaging cell line or a non-packaging cell line)
with a hybrid construct and a suitable helper adenovirus.
In a further aspect, the present invention provides a method for
producing large quantities of recombinant AAV particles with high
efficiency by employing the above methods, employing the hybrid
construct of this invention and collecting the rAAV particles from
a cell line transfected with the vector.
Other aspects and advantages of the present invention are described
further in the following detailed description of the preferred
embodiments thereof.
eom |
